ArticleMolecular syndromology2025
Gene Panel-Based Genotyping of 279 Turkish Maturity-Onset Diabetes of the Young Patients from Eastern Anatolia.
Article in Molecular syndromology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The aim of this study was to analyze the genotypic and clinical characteristics of Turkish patients with maturity-onset diabetes of the young (MODY) in Eastern Anatolia in order to improve the understanding of the genetic diversity and clinical manifestations of MODY. The findings should help to improve the diagnosis and management of monogenic diabetes. Methods: This retrospective study included 279 patients with suspected MODY, selected for age at presentation, family history, no pancreas autoantibodies, and minimal/no need for insulin. A next-generation sequencing panel was used for genetic analysis. The panel included 15 different genes. Results: Pathogenic variants were identified in 94% of the patients, with the majority being in GCK, HNF1A, and HNF4A. Variants in GCK were the most common (65%), followed by HNF1A (20%) and HNF4A (9%). Patients with GCK mutations exhibited mild fasting hyperglycemia, whereas HNF1A and HNF4A mutations were associated with progressive hyperglycemia. Conclusion: This study provides significant insights into the genotypic and clinical spectrum of MODY within a Turkish population. The detection of pathogenic variants in genes such as GCK, HNF1A, and HNF4A underscores the importance of comprehensive genetic testing in patients suspected of MODY. The results emphasize the need for personalized approaches to optimize the diagnosis and treatment of MODY. Detailed genetic and clinical assessments play a pivotal role in identifying at-risk individuals and tailoring management strategies. These findings could guide the development of targeted therapies and enhance the clinical outcomes of patients with monogenic diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.